[go: up one dir, main page]

MX2020001395A - Composiciones y su uso para suministro de iduronato-2-sulfatasa al sistema nervioso central. - Google Patents

Composiciones y su uso para suministro de iduronato-2-sulfatasa al sistema nervioso central.

Info

Publication number
MX2020001395A
MX2020001395A MX2020001395A MX2020001395A MX2020001395A MX 2020001395 A MX2020001395 A MX 2020001395A MX 2020001395 A MX2020001395 A MX 2020001395A MX 2020001395 A MX2020001395 A MX 2020001395A MX 2020001395 A MX2020001395 A MX 2020001395A
Authority
MX
Mexico
Prior art keywords
iduronate
sulfatase
compositions
delivery
nervous system
Prior art date
Application number
MX2020001395A
Other languages
English (en)
Other versions
MX390902B (es
Inventor
Lowe Kris
Shahrokh Zahra
Zhu Gaozhong
Christian James
Fahrner Rick
Pan Jing
Leah Wright Teresa
Calias Pericles
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46888843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020001395(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX2020001395A publication Critical patent/MX2020001395A/es
Publication of MX390902B publication Critical patent/MX390902B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a entre otras cosas, composiciones y métodos para suministro al SNC de enzimas lisosomales para tratamiento efectivo de enfermedades de almacenamiento lisosomal; en algunas modalidades, la presente invención incluye una formulación estable para administración intratecal directa al SNC que comprende una proteína Iduronato-2-sulfatasa (I2S), sal, y un tensoactivo de polisorbato para el tratamiento de Síndrome de Hunters.
MX2020001395A 2010-06-25 2011-06-25 Composiciones y su uso para suministro de iduronato-2-sulfatasa al sistema nervioso central. MX390902B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US36078610P 2010-07-01 2010-07-01
US38786210P 2010-09-29 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US201161495268P 2011-06-09 2011-06-09
PCT/US2011/041925 WO2011163649A2 (en) 2010-06-25 2011-06-25 Methods and compositions for cns delivery of iduronate-2-sulfatase

Publications (2)

Publication Number Publication Date
MX2020001395A true MX2020001395A (es) 2022-03-24
MX390902B MX390902B (es) 2025-03-21

Family

ID=46888843

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013000322A MX2013000322A (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa.
MX2020001395A MX390902B (es) 2010-06-25 2011-06-25 Composiciones y su uso para suministro de iduronato-2-sulfatasa al sistema nervioso central.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013000322A MX2013000322A (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa.

Country Status (25)

Country Link
US (1) US8545837B2 (es)
EP (3) EP3626258B1 (es)
JP (1) JP6045492B2 (es)
KR (5) KR102356192B1 (es)
CN (1) CN103179980B (es)
AU (4) AU2011270669B2 (es)
CA (1) CA2805448A1 (es)
CY (2) CY1122307T1 (es)
DK (1) DK2593131T3 (es)
ES (1) ES2754234T3 (es)
HR (1) HRP20191924T1 (es)
IL (3) IL284599B2 (es)
LT (1) LT2593131T (es)
ME (1) ME03649B (es)
MX (2) MX2013000322A (es)
NZ (2) NZ702808A (es)
PL (2) PL2593131T3 (es)
RS (1) RS59469B1 (es)
RU (1) RU2660348C2 (es)
SI (1) SI2593131T1 (es)
SM (1) SMT201900594T1 (es)
TW (1) TWI611808B (es)
UA (1) UA115649C2 (es)
WO (1) WO2011163649A2 (es)
ZA (1) ZA201300672B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158296A1 (en) 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
US8834874B2 (en) 2009-10-09 2014-09-16 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
PE20130589A1 (es) 2010-06-25 2013-05-19 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
US9320711B2 (en) * 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
HRP20191923T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku arilsulfataze a u cns
RS59469B1 (sr) 2010-06-25 2019-11-29 Shire Human Genetic Therapies Postupci i kompozicije za isporuku iduronat-2-sulfataze u cns
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
BR112014002219A2 (pt) 2011-07-05 2018-08-07 Bioasis Technologies Inc conjugados anticorpo p97 e métodos de sua utilização
EP2793933B1 (en) 2011-12-23 2019-04-17 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
AU2013240306A1 (en) 2012-03-30 2014-10-09 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate- 2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
CN104662150B (zh) * 2012-07-31 2018-07-10 比奥阿赛斯技术有限公司 脱磷酸化的溶酶体贮积症蛋白及其使用方法
EA039246B1 (ru) * 2012-12-06 2021-12-22 Шир Хьюман Дженетик Терапис, Инк. Способ лечения когнитивных нарушений, связанных с синдромом хантера
ES2774549T3 (es) 2013-03-13 2020-07-21 Bioasis Technologies Inc Fragmentos de P97 y usos de los mismos
EP4218769A3 (en) 2013-05-07 2023-10-18 Bio Blast Pharma Ltd. Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose
BR112015028605A8 (pt) * 2013-05-15 2019-12-24 Univ Minnesota uso de uma composição e uso de um imunossupressor e uma composição
US20160347821A1 (en) 2014-02-03 2016-12-01 Bioasis Technologies, Inc. P97 fusion proteins
AU2015219339B2 (en) 2014-02-19 2020-03-05 Bioasis Technologies Inc. P97-IDS fusion proteins
CA2943890A1 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
MA40954A (fr) * 2014-11-14 2017-09-19 Shire Human Genetic Therapies Détermination de niveaux de glycosaminoglycane par spectrométrie de masse
CA2985235A1 (en) 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
RS63927B1 (sr) * 2015-05-15 2023-02-28 Regenxbio Inc Povezani adenovirus za terapijsku isporuku u centralni nervni sistem
KR20170004814A (ko) * 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
DK3397270T5 (da) * 2015-12-30 2024-09-23 Green Cross Corp Sammensætninger til anvendelse i behandlingen af hunters syndrom
CA3010738A1 (en) * 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
MA44237A (fr) * 2016-02-17 2021-06-02 Takeda Pharmaceuticals Co Méthodes et compositions pour l'administration au système nerveux cental d'arylsulfatase a
RU2751235C2 (ru) * 2016-02-24 2021-07-12 Байомарин Фармасьютикал Инк. Терапевтические слитые белки направленного действия на основе лизосомных ферментов, соответствующие составы и их применения
SG11201808176TA (en) 2016-04-15 2018-10-30 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
MX2019007824A (es) 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
BR112019021569A2 (pt) 2017-04-14 2020-05-12 Regenxbio Inc. Precursor de iduronato-2-sulfatase humana recombinante glicosilada (ids), método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
JP7060235B2 (ja) * 2018-05-18 2022-04-26 国立大学法人広島大学 変異型イズロン酸－２－スルファターゼの機能回復薬剤のスクリーニング方法
KR102671857B1 (ko) * 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
JP2020002130A (ja) 2018-06-25 2020-01-09 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
KR102692543B1 (ko) * 2018-10-26 2024-08-07 재단법인 목암생명과학연구소 Ids를 포함하는 융합 단백질 및 이의 용도
US20220002688A1 (en) 2018-12-20 2022-01-06 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
WO2021067243A1 (en) * 2019-10-01 2021-04-08 Seelos Therapeutics, Inc. Trehalose formulations and uses thereof
KR20220148162A (ko) * 2020-01-29 2022-11-04 리젠엑스바이오 인크. 인간 신경 또는 신경아교 세포에 의해 생성된 재조합 인간 이두로네이트-2-설파타아제 (ids)를 사용한 점액다당류증 ii의 치료
WO2022173605A2 (en) 2021-02-10 2022-08-18 Regenxbio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AU735216B2 (en) * 1997-08-22 2001-07-05 Seikagaku Corporation Therapeutic agent for herniated intervertebral disc
JP4990434B2 (ja) 1998-12-07 2012-08-01 ジェンザイム・コーポレーション ポンペ病の処置
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US20020099025A1 (en) * 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
IL158623A0 (en) 2001-04-30 2004-05-12 Symbiontics Inc Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
IL161352A0 (en) 2001-10-16 2004-09-27 Symbiontics Inc Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
AU2003228722B2 (en) 2002-04-25 2009-06-25 Takeda Pharmaceutical Company Limited Treatment of alpha-galactosidase A deficiency
CA2487815A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
EP1587923B1 (en) 2003-01-22 2011-08-24 Duke University Improved constructs for expressing lysosomal polypeptides
ES2545619T3 (es) * 2003-01-31 2015-09-14 The Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20060029656A1 (en) 2004-02-03 2006-02-09 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
AU2005211775B2 (en) 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
EP1716232B9 (en) 2004-02-10 2010-10-13 ZyStor Therapeutics , Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
US20090297592A1 (en) 2005-05-11 2009-12-03 Jcr Pharmaceuticals Co., Ltd. Lipid Vesicle Composition
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
WO2008109677A2 (en) 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US7722865B2 (en) 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
CA2723412A1 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
HRP20191923T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku arilsulfataze a u cns
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
RS59469B1 (sr) 2010-06-25 2019-11-29 Shire Human Genetic Therapies Postupci i kompozicije za isporuku iduronat-2-sulfataze u cns
US9320711B2 (en) 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
WO2011163651A2 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
JP2012062312A (ja) * 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤

Also Published As

Publication number Publication date
IL284599B2 (en) 2024-02-01
PL3626258T3 (pl) 2022-01-17
KR20200104433A (ko) 2020-09-03
KR102603430B1 (ko) 2023-11-16
EP2593131B1 (en) 2019-08-21
LT2593131T (lt) 2019-10-25
AU2019203515A1 (en) 2019-06-06
NZ605863A (en) 2015-02-27
EP3626258B1 (en) 2021-08-04
RS59469B1 (sr) 2019-11-29
NZ702808A (en) 2016-08-26
AU2011270669B2 (en) 2017-01-05
MX2013000322A (es) 2013-04-03
IL284599A (en) 2021-08-31
TWI611808B (zh) 2018-01-21
IL268085B (en) 2021-07-29
PL2593131T3 (pl) 2020-01-31
CA2805448A1 (en) 2011-12-29
SI2593131T1 (sl) 2019-11-29
CY1122307T1 (el) 2021-01-27
WO2011163649A3 (en) 2012-05-10
AU2021202579A1 (en) 2021-05-27
KR102356192B1 (ko) 2022-02-08
ZA201300672B (en) 2017-11-29
US20110318323A1 (en) 2011-12-29
AU2017202219B2 (en) 2019-02-21
AU2011270669A1 (en) 2013-02-14
KR20130043165A (ko) 2013-04-29
AU2021202579B2 (en) 2023-06-29
EP3964229A1 (en) 2022-03-09
UA115649C2 (uk) 2017-12-11
IL284599B1 (en) 2023-10-01
MX390902B (es) 2025-03-21
US8545837B2 (en) 2013-10-01
DK2593131T3 (da) 2019-10-14
KR20220015506A (ko) 2022-02-08
SMT201900594T1 (it) 2019-11-13
AU2019203515B2 (en) 2021-01-28
IL268085A (en) 2019-08-29
JP2013530989A (ja) 2013-08-01
CN103179980B (zh) 2016-09-28
EP2593131A2 (en) 2013-05-22
IL223716B (en) 2019-08-29
EP2593131A4 (en) 2014-01-22
EP3626258A1 (en) 2020-03-25
KR20230159646A (ko) 2023-11-21
RU2660348C2 (ru) 2018-07-05
TW201206463A (en) 2012-02-16
KR20190008996A (ko) 2019-01-25
CY1124703T1 (el) 2022-07-22
WO2011163649A2 (en) 2011-12-29
HRP20191924T1 (hr) 2020-01-10
AU2017202219A1 (en) 2017-04-27
RU2012154575A (ru) 2014-07-27
ME03649B (me) 2020-07-20
JP6045492B2 (ja) 2016-12-14
KR102151889B1 (ko) 2020-09-04
ES2754234T3 (es) 2020-04-16
CN103179980A (zh) 2013-06-26

Similar Documents

Publication Publication Date Title
MX2020001395A (es) Composiciones y su uso para suministro de iduronato-2-sulfatasa al sistema nervioso central.
CY1124910T1 (el) Μεθοδοι και συνθεσεις για παραδοση στο κνς της αρυλοσουλφατασης α
BR112012033214A2 (pt) método e composições para distribuição no snc de iduronato-2-sulfatase
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
AR124140A2 (es) Formulaciones de anticuerpos
PE20120342A1 (es) Formulacion de anticuerpo
PH12014502778B1 (en) Antibody formulation
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
UA112549C2 (uk) Частинки на основі поліакрилату, що містять активну сполуку
CL2014003569A1 (es) Método de producción de iduronato-2-sulfatasa (i2s), que comprende cultivar células de mamíferos que coexpresan i2s recombinante y una enzima generadora formilglicina (fge); preparación de proteína i2s; composición farmacéutica; y uso para tratar síndrome de hunter.
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
EA201491578A1 (ru) Подкожное введение идуронат-2-сульфатазы
AR090244A1 (es) Formulacion de anticuerpo anti-selectina p
TR201007250A2 (tr) Selobioz içeren formülasyon.
CO7101241A2 (es) Formulaciones de antibióticos
IN2014CN04119A (es)
AR115942A2 (es) Composiciones farmacéuticas estables para la administración intratecal de arisulfatasa a y envases que las comprenden
AR122178A2 (es) Composición farmacéutica líquida y proceso para prepararla
CL2015002906A1 (es) Suministro al sistema nervioso central de agentes terapéuticos (divisional de solicitud 3656-2012)
TR201203087A2 (tr) Seftibüten ve klavulanik asit formülasyonları.
TR201203085A2 (tr) Sefetamet ve klavulanik asit içeren bileşimler.
TR200806299A2 (tr) Çözünürlük artırıcı farmasötik formülasyon
TH175929A (th) สูตรตำรับของแอนติบอดี้ (Antibody Formulation)